公开(公告)号：US20220280529A1

公开(公告)日：2022-09-08

申请号：US17192597

申请日：2021-03-04

申请人： Theralase Technologies, Inc.

发明人： Roger DUMOULIN-WHITE ,  Arkady MANDEL

IPC分类号： A61K31/555 ,  A61K39/125

摘要： A method for eliciting an immune response in a patient includes the sequential steps of: providing an immunogenic composition including an immunogen; adding a metal-based coordination complex to the immunogenic composition to inactivate or attenuate the immunogen; and administering the immunogenic composition to the patient so as to elicit the immune response against the immunogen. A method for preparing an attenuated immunogenic composition includes the steps of: providing an immunogenic composition including an immunogen; and adding a metal-based coordination complex to the immunogenic composition to inactivate or attenuate the immunogen in the immunogenic composition to provide the attenuated immunogenic composition.

公开(公告)号：US20220249490A1

公开(公告)日：2022-08-11

申请号：US17505364

申请日：2021-10-19

申请人： The Trustees of the University of Pennsylvania

发明人： Daniel Sterman ,  Steven Albelda

IPC分类号： A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61K31/415 ,  A61K31/7068 ,  A61K35/761 ,  C12N15/86 ,  C07K14/47 ,  A61K38/21 ,  A61K31/635 ,  A61K31/555 ,  A61K33/243 ,  A61K9/00 ,  A61K39/12 ,  A61K39/395

摘要： Gene therapy based combination therapy for malignant pleural mesothelioma (“MPM”) that is resistant to or recurrent after chemotherapy employing a viral vector containing a human interferon transgene, followed by standard first- or second-line cytotoxic chemotherapy. Overall survival rate was significantly higher than historical controls in the second-line group.

公开(公告)号：US11382895B2

公开(公告)日：2022-07-12

申请号：US12993469

申请日：2009-05-26

申请人： Brian J. Day ,  Carl W. White

发明人： Brian J. Day ,  Carl W. White

IPC分类号： A61K45/06 ,  A61P39/06 ,  A61K31/555 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/409

摘要： Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins.

公开(公告)号：US20220211987A1

公开(公告)日：2022-07-07

申请号：US17656531

申请日：2022-03-25

申请人： TARIS Biomedical LLC

发明人： Heejin Lee ,  Karen Daniel ,  Matthew Sansone

IPC分类号： A61M31/00 ,  A61K9/00 ,  A61K31/137 ,  A61K31/167 ,  A61K31/216 ,  A61K31/337 ,  A61K31/407 ,  A61K31/438 ,  A61K31/555 ,  A61K31/7068 ,  A61K33/243

摘要： Implantable drug delivery devices include a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, and a drug contained in the drug reservoir lumen, wherein the first wall structure is impermeable to the drug and the second wall structure is permeable to the drug. Methods of providing controlled release of drug to a patient include deploying a drug delivery device in the patient releasing a drug from the drug reservoir lumen via diffusion through the second wall structure.

公开(公告)号：US20220142926A1

公开(公告)日：2022-05-12

申请号：US17350268

申请日：2021-06-17

申请人： Japan Tobacco Inc.

发明人： Masayoshi FUKUSHIMA ,  Kazuhiro ORITA ,  Shogo YAMANE

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/194 ,  A61K33/26 ,  A61K47/32 ,  A61K31/555

摘要： The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.

公开(公告)号：US11325980B2

公开(公告)日：2022-05-10

申请号：US16085511

申请日：2017-03-15

申请人： SEATTLE GENETICS, INC.

发明人： Django Sussman ,  Fu Li ,  Ana Kostic

IPC分类号： A61K31/337 ,  A61K31/555 ,  A61K31/704 ,  C07K16/30 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  A61K9/00 ,  A61K39/00

摘要： The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.

公开(公告)号：US20220133739A1

公开(公告)日：2022-05-05

申请号：US17576197

申请日：2022-01-14

申请人： EGETIS THERAPEUTICS AB

发明人： Jacques NÄSSTRÖM ,  Sven JACOBSSON ,  Dennis HENRIKSEN ,  James VAN ALSTINE

IPC分类号： A61K31/555 ,  A61K31/167 ,  A61K31/198 ,  A61K31/6615 ,  A61P1/16 ,  A61P13/12 ,  A61K9/08 ,  A61K9/10 ,  A61K9/19

摘要： Methods for treating and/or protecting against acute liver failure and other hepatotoxicities in an individual employ a combination of a first active agent comprising N-acetylcysteine and a second active agent comprising a manganese complex selected from the group consisting of (i) a calcium manganese mixed metal complex of N,N′-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N′-diacetic acid (DPDP) having a molar ratio of calcium to manganese in a range of from 1 to 10, or a pharmaceutically acceptable salt thereof, (ii) a mixture of manganese DPDP (MnDPDP), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing DPDP compound, or (iii) a mixture of manganese pyridoxyl ethylenediamine (MnPLED), or a pharmaceutically acceptable salt thereof, and a non-manganese-containing pyridoxyl ethylenediamine (PLED) compound.

公开(公告)号：US11286271B2

公开(公告)日：2022-03-29

申请号：US17264719

申请日：2019-07-31

申请人： The University of Hong Kong

发明人： Chi Ming Che ,  Tsz Lung Lam ,  Ka Chung Tong

IPC分类号： C07F15/00 ,  A61K31/555 ,  A61P35/00 ,  A61N5/06

摘要： Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.

公开(公告)号：US20220088042A1

公开(公告)日：2022-03-24

申请号：US17327863

申请日：2021-05-24

申请人： Bexion Pharmaceuticals, Inc. ,  University of Cincinnati

发明人： Xiaoyang Qi ,  Olugbenga Olowokure ,  Ray Takigiku

IPC分类号： A61K31/685 ,  A61K38/17 ,  A61K31/7068 ,  A61K45/06 ,  A61K9/00 ,  A61P35/00 ,  A61K31/337 ,  A61K9/127 ,  A61K9/107 ,  A61K31/513 ,  A61K47/24 ,  A61K31/695 ,  A61K38/16 ,  A61K31/4745 ,  A61K31/555 ,  A61K31/519

摘要： Disclosed herein, according to the present invention, are methods of treating pancreatic cancer comprising administering a first pharmaceutical composition comprising Saposin C and dioleoylphosphatidylserine (SapC-DOPS) and administering a second pharmaceutical composition comprising an anti-neoplastic agent. Optionally, additional pharmaceutical compositions may be administered. Also disclosed are methods of inhibiting tumor growth. Also disclosed are kits for the treatment of pancreatic cancer comprising at least two pharmaceutical compositions, wherein a first pharmaceutical composition comprises SapC-DOPS and wherein a second pharmaceutical composition comprises a first antineoplastic agent. Also disclosed herein are combination therapeutics comprising a first pharmaceutical composition comprising SapC-DOPS and at least a second pharmaceutical composition comprising an antineoplastic agent, wherein the first and second pharmaceutical compositions are formulated separately to be used in the form of a kit where they are present together.

公开(公告)号：US20220088031A1

公开(公告)日：2022-03-24

申请号：US17423959

申请日：2020-01-31

申请人： Health Research, Inc.

发明人： Dhyan Chandra ,  Rahul Kumar ,  Neelu Yadav

IPC分类号： A61K31/555 ,  A61K31/337 ,  A61K31/136 ,  A61K31/565 ,  A61K31/19 ,  A61P35/00 ,  A61K31/426

摘要： A method for treating prostate cancer in a subject involves selecting a subject having prostate cancer and cytochrome c-deficiency, and administering, to the selected subject, a therapeutically effective amount of one or more agents capable of restoring cytochrome-c activity. Also presented is a method of inducing apoptosis in drug resistant cancer cells involving selecting drug resistant cancer cells having cytochrome-c deficiency, and administering to the selected cells, one or more agents that restore cytochrome-c activity in an amount effective to sensitize said cancer cells to drug induced apoptosis. A combination therapeutic comprising one or more agents increases cytochrome-c activity and efficacy of a chemotherapeutic agent. Another method involves selecting a subject having cancer, and obtaining a cell sample including tumor tissues/biopsy and blood samples from said subject, and further involves measuring cytochrome-c expression levels and Drp1 phosphorylation levels in said sample.